HAYA Therapeutics Co-Founders Win Inaugural Andreas & Thomas Struengmann Award [Yahoo! Finance]
BioNTech SE - American Depositary Shares (BNTX)
Company Research
Source: Yahoo! Finance
LAUSANNE, Switzerland & SAN DIEGO, July 01, 2024 BUSINESS WIRE HAYA Therapeutics, SA , a company developing RNA-guided programmable precision medicines focused on long non-coding RNAs (lncRNAs), today announced that HAYA's Co-Founders Samir Ounzain and Daniel Blessing have received the inaugural Andreas & Thomas Struengmann Award Recognizing entrepreneurial vision and talent in the life sciences among the DACH region, which includes Germany, Austria and Switzerland, the award honors the efforts of Drs. Ounzain and Blessing in creating a company developing an innovative RNA therapeutic approach targeting lncRNAs for heart disease and a broad range of chronic and underserved conditions. Representatives from the award committee presented the award and the €100,000 cash prize to Drs. Ounzain and Blessing at the Festival of the Future at the Deutsches Museum in Munich on Friday, June 28, 2024. "It is a privilege to receive the Andreas & Thomas Struengmann Award, named to honor two pio
Show less
Read more
Impact Snapshot
Event Time:
BNTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BNTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BNTX alerts
High impacting BioNTech SE - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
BNTX
News
- Andreas & Thomas Struengmann Award Honors HAYA Therapeutics Co-founders as Inaugural Winners [Yahoo! Finance]Yahoo! Finance
- Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union [Yahoo! Finance]Yahoo! Finance
- Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union GlobeNewswire
- BioNTech SE (NASDAQ: BNTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $113.00 price target on the stock.MarketBeat
- Meta axed his AI biology research team. Now this ‘Meta AI Mafia' member's new startup has $142 million to chase his protein-generating dream [Yahoo! Finance]Yahoo! Finance
BNTX
Earnings
- 5/6/24 - Miss
BNTX
Sec Filings
- 6/28/24 - Form 6-K
- 6/24/24 - Form 6-K
- 6/17/24 - Form 6-K
- BNTX's page on the SEC website